about
The cancer stem cell: evidence for its origin as an injured autoreactive T cellPostoperative Acute Pulmonary Embolism Following Pulmonary ResectionsTrousseau's syndrome: multiple definitions and multiple mechanismsMicrovesicle-associated tissue factor and Trousseau's syndromeIn situ detection of tissue factor within the coronary intima in rat cardiac allograft vasculopathy.Cardiopulmonary bypass in patients with pre-existing coagulopathyProcoagulant activity of the MC28 fibrosarcoma cell line in vitro and in vivo.Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration.Tissue factor-factor VIIa signaling.The hemostatic system and angiogenesis in malignancy.Abnormalities in hemostasis in acute promyelocytic leukemia.Tissue factor - a therapeutic target for thrombotic disorders.Clinical use of the low-molecular-weight heparins in cancer patients: focus on the improved patient outcomes.Glomerular tissue factor expression in crescentic glomerulonephritis. Correlations between antigen, activity, and mRNA.Tissue factor and cancer metastasis: the role of intracellular and extracellular signaling pathwaysThe Role of Putative Phosphatidylserine-Interactive Residues of Tissue Factor on Its Coagulant Activity at the Cell Surface.Effect of tissue factor deficiency on mouse and tumor development.Differential expression of human tissue factor in normal mammary epithelial cells and in carcinomasTissue factor expression as a possible determinant of thromboembolism in ovarian cancerA new method to determine tissue specific tissue factor thrombomodulin activities: endotoxin and particulate air pollution induced disbalance.Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis.Basic mechanisms and pathogenesis of venous thrombosis.Primary prevention of venous thromboembolism.Absence of tissue factor is characteristic of lymphoid malignancies of both T- and B-cell originThe Pathogenetic Role of Apoptosis in Hypercoagulable States.miR-20b regulates expression of proteinase-activated receptor-1 (PAR-1) thrombin receptor in melanoma cells.Vascular endothelial growth factor activates nuclear factor of activated T cells in human endothelial cells: a role for tissue factor gene expression.Cell surface proteomics identifies molecules functionally linked to tumor cell intravasation.Thrombin inhibitor, argatroban, prevents tumor cell migration and bone metastasis.Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy.Binding of factor VIIa to tissue factor on keratinocytes induces gene expression.Analysis of tissue factor and tissue factor pathway inhibitor expression in human colorectal carcinoma cell lines and metastatic sublines to the liver.Rat prostate tumors express cancer procoagulant, an activator of coagulation factor X.Cut-off value of D-dimer for prediction of deep venous thrombosis before treatment in ovarian cancer.Trousseau syndrome presenting with penile gangreneSharing tissue factor: a winning strategy in tumorigenesis.Superior sagittal sinus thrombosis as the initial presentation of renal cell carcinoma.Thrombogenic role of cells undergoing apoptosis.Hemostatic and fibrinolytic status in patients with ovarian cancer and benign ovarian cysts: could D-dimer and antithrombin III levels be included as prognostic markers for survival outcome?An Overview of Thrombophilia and Associated Laboratory Testing.
P2860
Q25256839-11B9893D-0A87-4A67-8B81-A99EA7FFBB8BQ26782116-9790867F-AC4F-4ACD-9270-562FFA1B3218Q28301882-2E5F4CA0-DAD3-40CB-B13E-23789B8A8D9AQ29026182-A0305F73-3BCA-4A54-B51E-E51188646AECQ31920320-C6AFB553-B431-48A9-9732-30962D13F5E7Q33365668-195B9E06-B6A9-4F28-A1E2-F2F95F63F848Q33490882-4215BE58-6B6D-488D-8409-4E6F92FCEFF3Q33723243-A7CE4371-B937-4E32-8326-0FC01DEA8FEAQ33726774-B032642D-00B1-4D2E-BE06-5EC8F2E51956Q34425462-B647AE0D-8235-4A37-A35B-BC1740AB676AQ34580613-865ED4FF-C117-4AC6-B5DF-CCB29093878CQ34837564-54C786E6-ED1F-4673-9CA3-FC882E647712Q35368813-C762976B-3924-40AC-8714-5BF6D27A94E6Q35796523-9D4DEBC3-EBAD-4B76-B188-AF07EDBA6C6AQ35926915-84DBBF9F-A82C-44AF-99D4-20C07BFE9FA5Q36062304-5F43D92A-8309-4B95-9EE9-F9D9E15B9208Q36243054-0A56EDEA-4594-433A-BD6C-B63F2FD577F1Q36437481-16C8AB0F-544B-41E3-B794-E372692794A8Q36609724-8DC364A2-BA52-43DC-A62D-964C7A7BF610Q36942543-8C67C203-A8C8-487E-8388-254E66AF1F73Q37380155-55542F6F-29E1-4D13-8B7E-9BA0D3DCD255Q37388336-F6011733-0E61-45E5-9F0A-D5790A15A08AQ37998002-766FCB8C-BA77-4D78-965B-CA54665F8A31Q38496748-D2845DCB-1C7A-458E-B2E4-4BD6442464E5Q38897750-58996CEF-D911-4BA4-A346-85160CE9D1F3Q39036055-C354FD11-A451-4B96-8247-73E84A131491Q39444857-288432F6-6BA2-44F8-9082-73D103EE0163Q39956901-2EEA2919-A56B-4E3A-AF4E-17907792B407Q40493072-ACD697C4-E7A1-4588-BEB5-863A8E889043Q40870045-D677F8EA-5E97-4728-8D32-13091034B5A6Q40897781-BC0D6D1C-CF33-4EDB-BB6B-69716B7F2C46Q41090311-4F4A8962-6797-416F-87C0-1F0D4B32F1AEQ42007941-7BB6D261-DBB8-4C74-9CCC-8A5A3E7B6440Q42277708-F31702C4-15BC-47B3-A737-F7BFD982CC57Q42315003-62C49B2E-5741-426A-AC64-F2FA0D1AA199Q43128770-1F290EC1-4BCF-4A31-BEF7-93256239F777Q43193000-A1D98CF6-6B9A-4C7C-BDFF-2850752401D6Q43795708-9881483B-0D79-41D5-95D4-CCF4BAC158D1Q44492258-09021428-9D57-432A-91A0-647BAF6FD5CDQ47957644-7B8ECCB8-BD34-48A4-8DFC-9014910E183F
P2860
description
1992 nî lūn-bûn
@nan
1992 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Tissue factor as a tumor procoagulant.
@ast
Tissue factor as a tumor procoagulant.
@en
type
label
Tissue factor as a tumor procoagulant.
@ast
Tissue factor as a tumor procoagulant.
@en
prefLabel
Tissue factor as a tumor procoagulant.
@ast
Tissue factor as a tumor procoagulant.
@en
P356
P1476
Tissue factor as a tumor procoagulant.
@en
P2093
P2888
P304
P356
10.1007/BF01307181
P577
1992-11-01T00:00:00Z